6.04
-0.29(-4.58%)
Currency In USD
| Previous Close | 6.33 |
| Open | 6.22 |
| Day High | 6.33 |
| Day Low | 5.99 |
| 52-Week High | 17 |
| 52-Week Low | 2.68 |
| Volume | 2.4M |
| Average Volume | 9.17M |
| Market Cap | 471.46M |
| PE | -1.86 |
| EPS | -3.24 |
| Moving Average 50 Days | 7.03 |
| Moving Average 200 Days | 9.97 |
| Change | -0.29 |
If you invested $1000 in Replimune Group, Inc. (REPL) since IPO date, it would be worth $398.42 as of September 09, 2025 at a share price of $6.04. Whereas If you bought $1000 worth of Replimune Group, Inc. (REPL) shares 5 years ago, it would be worth $242.67 as of September 09, 2025 at a share price of $6.04.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Replimune Announces Type A Meeting Scheduled with FDA
GlobeNewswire Inc.
Sep 02, 2025 12:00 PM GMT
WOBURN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that a Type A meeting with the U.S. Food a
Replimune Receives Complete Response Letter from FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
GlobeNewswire Inc.
Jul 22, 2025 11:00 AM GMT
WOBURN, Mass., July 22, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced that the U.S. Food and Drug Administration
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting
GlobeNewswire Inc.
Jun 01, 2025 2:00 PM GMT
- RP1 plus nivolumab generated robust responses in both injected and non-injected lesions - - Deep/visceral injections, including into the liver and lung, resulted in numerically higher rates of response compared to superficial injections only and we